Natixis’s Beam Therapeutics BEAM Stock Holding History

Natixis’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-92,619	Closed	-$4.41M	–	1105
2022 Q3	$4.41M	Buy	92,619 +33,959	+58%	+$1.94M	0.02%	440
2022 Q2	$2.27M	Buy	+58,660	New	+$2.33M	0.01%	637

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Natixis's BEAM Position: Q4 2022 in Review

Natixis sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 92,619 shares — an estimated $4.41M sold.

Natixis first reported a position in BEAM in Q2 2022 and held it in 2 quarters. The position peaked at $4.41M in Q3 2022. 209 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

Natixis reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
Natixis sold 92,619 Beam Therapeutics shares in Q4 2022, an estimated $4.41M.
Natixis first reported a position in Beam Therapeutics in Q2 2022 and held it in 2 quarters.
Natixis's Beam Therapeutics position peaked at $4.41M in Q3 2022.
209 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.